MedTrace Logo

The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients

NCT03991910 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2021-08-16

No results posted yet for this study

Summary

Objective propose: to investigate the effect of Ramipril in suppressing ST2 (suppression of tumorigenicity 2) in the cardiac mitral valve in patients with Rheumatic Heart Disease. We hypothesized that we hypothesized that ramipril will improve rheumatic mitral valve fibrosis through the downregulation of ST2.

Conditions

  • Rheumatic Heart Disease
  • Mitral Stenosis
  • Rheumatic Mitral Stenosis
  • Fibrosis; Heart
  • ACE Inhibitor

Interventions

DRUG

Placebos

the control group will be given placebo inside a capsule, so study participant won't be able to know the drug and doses inside the capsule (for masking). Placebo will be given until 5 days prior to Mitral valve replacement surgery.

DRUG

Ramipril 5Mg Oral Capsule

the treatment group will be given each Ramipril 2,5 mg inside a capsule as an initial dose, for 2 weeks. If there is no serious adverse effect in the observation period of 2 weeks, Ramipril 5 mg inside a capsule will be given for the next weeks until 5 days before the mitral valve surgery date. Study participant won't be able to know the drug and doses inside the capsule (for masking)

Sponsors & Collaborators

  • Indonesia University

    lead OTHER

Principal Investigators

  • Ade Meidian Ambari, MD,FIHA · Universitas Indonesia, RSPJN harapan kita

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-27
Primary Completion
2024-08-08
Completion
2024-08-08

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03991910 on ClinicalTrials.gov